

Bangladesh Vaccine Support

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Bangladesh				
2. Grant Number: 1216-BGD-09a-X / 1316-BGD-09a-Y				
3. Date of Decision Letter: 6 October 2015 (replaces the previous Decision Letter for Measles issued on 23 December 2014)				
4. Date of the Partnership Framework Agreement: 26 June 2013				
5. Programme Title: NVS, Measles second dose Routine				
6. Vaccine type: Measles-Rubella				
7. Requested product presentation and formulation of vaccine: Measles-Rubella, 10 dose(s) per vial, LYOPHILISED				
8. Programme Duration¹: 2012 -2016				
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):				
	2012-2014	2015	2016	Total ²
Programme Budget (US\$)	US\$5,388,538 ³	US\$1,854,000	US\$1,471,000	US\$8,713,538
10. Vaccine Introduction Grant: Not applicable				
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴				
Type of supplies to be purchased with GAVI funds in each year (1216-BGD-09a-X)		2015		2016
Vaccine Doses		5,177,300		3,802,000
Annual Amounts (US\$)		US\$1,654,500		US\$1,353,000
Type of supplies to be purchased with GAVI funds in each year (1316-BGD-09a-Y)		2015		2016
AD Syringes		3,174,100		1,984,600
Re-constitution Syringes		569,500		418,300
Safety Boxes		34,925		26,450
Annual Amounts (US\$)		US\$199,500		US\$118,000
The annual amounts for vaccine doses and supplies are equal to the programme budget for each year.				
12. Procurement agency: UNICEF				
13. Self-procurement: Not applicable				

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

14. Co-financing obligations: Not Applicable		
15. Operational support for campaigns: Not applicable		
16. Additional documents to be delivered for future disbursements: Not applicable		
Reports, documents and other deliverables	Due dates	
Annual Progress Report or equivalent	To be agreed with GAVI Secretariat	
17. Financial Clarifications: Not Applicable		
18. Other conditions:		
Country has presented an official request to GAVI and UNICEF to switch from measles vaccine to measles- rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the Rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.		
	2015	2016
Number of doses of vaccines for Measles Second Dose approved by GAVI.	3,177,300 ⁵	3,802,000
Amount for vaccines approved by GAVI in US\$ (excluding freight and insurance).	US\$953,190	US\$1,216,640
Number of doses of Measles-Rubella vaccine that can be purchased with GAVI support.	1,649,118	1,994,492
Number of doses of Measles-Rubella vaccine to be funded by country.	1,528,182	1,807,508
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	US\$883,289	US\$1,102,580
<p>In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Cost Estimate to UNICEF, with a clear reference to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.</p> <p>In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi <u>immediately</u> in order to agree on an appropriate arrangement.</p>		

Signed by,



On behalf of Gavi

Hind Khatib-Othman
 Managing Director, Country Programmes
 6 October 5, 2015

⁵ Note: 2015 Number of doses of vaccine for Measles Second Dose approved by Gavi, reflects a previous shipment of two million measles doses.

